Lord’s Mark Industries has bought an 85% stake in Renalyx Health Systems, the Bengaluru-based med-tech firm behind India’s first indigenous AI- and cloud-enabled smart hemodialysis machine a move aimed at scaling advanced dialysis care and expanding renal-care technology across India.
Glimpse:
Under the acquisition, Renalyx will become the R&D arm of Lord’s Mark Industries. The firm’s flagship dialysis system RENALYX RxT 21 offers AI-driven monitoring, cloud connectivity, real-time data analytics and remote-care readiness. The acquisition is seen as a push to democratise dialysis access, especially in underserved areas, while supporting the home-grown medtech manufacturing ecosystem.
Lord’s Mark Industries Ltd., a diversified healthcare and technology-led group, has announced the acquisition of an 85% stake in Renalyx Health Systems Private Limited. Renalyx, headquartered in Bengaluru, is known for developing a fully indigenous, AI- and cloud-enabled smart hemodialysis machine one of the first in India.
Post-acquisition, Renalyx will operate as the R&D division of Lord’s Mark Industries, with a mission to further innovate in renal (and related) care technologies. The flagship dialysis machine, RxT 21, integrates real-time remote monitoring, EMR and clinical-connectivity, automated dialysis protocols, and advanced safety/filtration features.
By acquiring majority control, Lord’s Mark plans to scale up manufacturing and distribution making dialysis more accessible and affordable across India, including rural and semi-urban regions that often lack advanced renal-care infrastructure. The acquisition aligns with broader national goals of strengthening domestic med-tech capacity under “Make in India” and reducing dependence on imported equipment.
“With Renalyx onboard, we’re not just buying a company we’re investing in a future where dialysis becomes smart, connected and accessible for every patient, regardless of geography.”
By
HB Team
